Capricor Therapeutics, Inc. (CAPR)
NASDAQ: CAPR · Real-Time Price · USD
28.87
-0.71 (-2.40%)
At close: May 22, 2026, 4:00 PM EDT
28.99
+0.12 (0.42%)
After-hours: May 22, 2026, 6:58 PM EDT
Capricor Therapeutics Employees
Capricor Therapeutics had 231 employees as of December 31, 2025. The number of employees increased by 71 or 44.38% compared to the previous year.
Employees
231
Change (1Y)
71
Growth (1Y)
44.38%
Revenue / Employee
n/a
Profits / Employee
-$496,077
Market Cap
1.67B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 231 | 71 | 44.38% | 231 | 0 |
| Dec 31, 2024 | 160 | 58 | 56.86% | 160 | 0 |
| Dec 31, 2023 | 102 | 28 | 37.84% | 101 | 1 |
| Dec 31, 2022 | 74 | 26 | 54.17% | 74 | 0 |
| Dec 31, 2021 | 48 | 22 | 84.62% | 48 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Recursion Pharmaceuticals | 600 |
| AbCellera Biologics | 562 |
| Agios Pharmaceuticals | 540 |
| Intellia Therapeutics | 377 |
| Nuvation Bio | 307 |
| Harmony Biosciences Holdings | 293 |
| Monte Rosa Therapeutics | 187 |
| Innoviva | 159 |
CAPR News
- 11 days ago - Capricor Therapeutics price target lowered to $38 from $43 at Roth Capital - TheFly
- 13 days ago - Capricor Therapeutics Q1 Earnings Call Highlights - MarketBeat
- 13 days ago - Capricor Therapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 13 days ago - Capricor Therapeutics Earnings release: Q1 2026 - Filings
- 13 days ago - Capricor Therapeutics Quarterly report: Q1 2026 - Filings
- 13 days ago - Capricor Therapeutics options imply 9.4% move in share price post-earnings - TheFly
- 13 days ago - Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 17 days ago - Capricor files suit against NS Pharma over Deramiocel distribution deal - TheFly